Treatment of severe proliferative lupus nephritis: the current state
| Autor: | K N Lai, Chi Chiu Mok, Raymond Woon Sing Wong |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Biological Response Modifiers - therapeutic use
Cyclophosphamide - therapeutic use Cyclophosphamide Immunology Lupus nephritis Review Disease Pharmacology Drug Administration Schedule General Biochemistry Genetics and Molecular Biology Lupus Nephritis - drug therapy Rheumatology medicine Humans Immunologic Factors Immunology and Allergy Initial treatment Biological response modifiers business.industry Immunosuppressive Agents - therapeutic use medicine.disease Lupus Nephritis Apheresis Drug Administration Schedulex Drug Therapy Combination business Nucleoside Immunosuppressive Agents medicine.drug |
| Zdroj: | Annals of the Rheumatic Diseases. 62:799-804 |
| ISSN: | 0003-4967 |
| DOI: | 10.1136/ard.62.9.799 |
| Popis: | Despite the development of new modalities, cyclophosphamide (CYC) remains the preferred initial treatment for severe proliferative lupus nephritis. Controversies continue about the best route, dosage, and duration of CYC treatment. For recalcitrant disease, new immunosuppressive and immunomodulating agents, immunoablative high dose CYC, nucleoside analogues, apheresis, and the biological response modifiers can be considered. published_or_final_version |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|